tiprankstipranks
Compass Pathways Plc (MX:CMPSN)
NASDAQ:CMPSN
Mexico Market
CMPSN
COMPASS Pathways
RESEARCH TOOLSreports

COMPASS Pathways (CMPSN) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

CMPSN Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
COMPASS
Pathways
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CMPSN Stock 12 Month Forecast

Average Price Target

$437.72
Based on 13 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $437.72 with a high forecast of $1,225.62 and a low forecast of $297.65. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"78":"$78","365":"$365","652":"$652","939":"$939","1226":"$1,226"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1225.6189379,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.23K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":437.72104924999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$437.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":297.65031349,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$297.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[78,365,652,939,1226],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242,317.6629952230769,393.3259904461538,468.9889856692308,544.6519808923076,620.3149761153845,695.9779713384615,771.6409665615384,847.3039617846154,922.9669570076923,998.6299522307692,1074.292947453846,1149.955942676923,{"y":1225.6189379,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242,257.05546532692307,272.11093065384614,287.1663959807692,302.2218613076923,317.27732663461535,332.3327919615384,347.38825728846155,362.44372261538456,377.4991879423077,392.5546532692307,407.6101185961538,422.6655839230769,{"y":437.72104924999996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242,246.2807933453846,250.56158669076922,254.84238003615383,259.12317338153844,263.40396672692304,267.68476007230765,271.9655534176923,276.24634676307693,280.52714010846154,284.80793345384615,289.08872679923076,293.36952014461536,{"y":297.65031349,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,226Average Price Target$437.72Lowest Price Target$297.65
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:CMPSN
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$1,225.62
Buy
―
Reiterated
07/20/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), COMPASS Pathways (NASDAQ: CMPS) and Alkermes (NASDAQ: ALKS)
TD Cowen Analyst forecast on MX:CMPSN
Ritu Baral
TD Cowen
TD Cowen
$507.76
Buy
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), NovoCure (NASDAQ: NVCR) and Bristol-Myers Squibb (NYSE: BMY)
LifeSci Capital Analyst forecast on MX:CMPSN
Francois Brisebois
LifeSci Capital
LifeSci Capital
$420.21
Buy
―
Reiterated
07/11/26
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)
Evercore ISI Analyst forecast on MX:CMPSN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$140.07→$367.69
Buy
―
Upgraded
07/08/26
Compass Pathways upgraded to Outperform from In Line at Evercore ISICompass Pathways upgraded to Outperform from In Line at Evercore ISI
Stifel Nicolaus Analyst forecast on MX:CMPSN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$245.12→$367.69
Buy
―
Assigned
07/08/26
Compass Pathways study data supports benefit of second dose, says StifelCompass Pathways study data supports benefit of second dose, says Stifel
Canaccord Genuity Analyst forecast on MX:CMPSN
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$350.18
Buy
―
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)
Wolfe Research Analyst forecast on MX:CMPSN
Rudy Li
Wolfe Research
Wolfe Research
$315.16
Buy
―
Reiterated
07/07/26
Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch
RBC Capital Analyst forecast on MX:CMPSN
Leonid Timashev
RBC Capital
RBC Capital
$385.19
Buy
―
Reiterated
07/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)
Oppenheimer Analyst forecast on MX:CMPSN
Jay Olson
Oppenheimer
Oppenheimer
$350.18
Buy
―
Reiterated
07/07/26
Compass Pathways data strengthens launch prospects, says OppenheimerCompass Pathways data strengthens launch prospects, says Oppenheimer
BTIG Analyst forecast on MX:CMPSN
Thomas Shrader
BTIG
BTIG
$245.12→$437.72
Buy
―
Reiterated
07/07/26
Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)
Morgan Stanley Analyst forecast on MX:CMPSN
Judah Frommer
Morgan Stanley
Morgan Stanley
$297.65
Buy
―
Reiterated
07/07/26
Compass new data validates COMP360 durability profile, says Morgan StanleyCompass new data validates COMP360 durability profile, says Morgan Stanley
Maxim Group Analyst forecast on MX:CMPSN
Michael Okunewitch
Maxim Group
Maxim Group
$350.18
Buy
―
Assigned
05/15/26
Compass Pathways price target raised to $20 from $12 at MaximCompass Pathways price target raised to $20 from $12 at Maxim
Jefferies Analyst forecast on MX:CMPSN
Andrew Tsai
Jefferies
Jefferies
$315.16
Buy
―
Reiterated
05/14/26
Jefferies Remains a Buy on COMPASS Pathways (CMPS)
B. Riley Securities Analyst forecast on MX:CMPSN
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$297.65
Buy
―
Initiated
04/24/26
Compass Pathways initiated with a Buy at B. RileyCompass Pathways initiated with a Buy at B. Riley
Cantor Fitzgerald Analyst forecast on MX:CMPSN
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$350.18
Buy
―
Reiterated
01/07/26
Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:CMPSN
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$1,225.62
Buy
―
Reiterated
07/20/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), COMPASS Pathways (NASDAQ: CMPS) and Alkermes (NASDAQ: ALKS)
TD Cowen Analyst forecast on MX:CMPSN
Ritu Baral
TD Cowen
TD Cowen
$507.76
Buy
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), NovoCure (NASDAQ: NVCR) and Bristol-Myers Squibb (NYSE: BMY)
LifeSci Capital Analyst forecast on MX:CMPSN
Francois Brisebois
LifeSci Capital
LifeSci Capital
$420.21
Buy
―
Reiterated
07/11/26
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)
Evercore ISI Analyst forecast on MX:CMPSN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$140.07→$367.69
Buy
―
Upgraded
07/08/26
Compass Pathways upgraded to Outperform from In Line at Evercore ISICompass Pathways upgraded to Outperform from In Line at Evercore ISI
Stifel Nicolaus Analyst forecast on MX:CMPSN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$245.12→$367.69
Buy
―
Assigned
07/08/26
Compass Pathways study data supports benefit of second dose, says StifelCompass Pathways study data supports benefit of second dose, says Stifel
Canaccord Genuity Analyst forecast on MX:CMPSN
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$350.18
Buy
―
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)
Wolfe Research Analyst forecast on MX:CMPSN
Rudy Li
Wolfe Research
Wolfe Research
$315.16
Buy
―
Reiterated
07/07/26
Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch
RBC Capital Analyst forecast on MX:CMPSN
Leonid Timashev
RBC Capital
RBC Capital
$385.19
Buy
―
Reiterated
07/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)
Oppenheimer Analyst forecast on MX:CMPSN
Jay Olson
Oppenheimer
Oppenheimer
$350.18
Buy
―
Reiterated
07/07/26
Compass Pathways data strengthens launch prospects, says OppenheimerCompass Pathways data strengthens launch prospects, says Oppenheimer
BTIG Analyst forecast on MX:CMPSN
Thomas Shrader
BTIG
BTIG
$245.12→$437.72
Buy
―
Reiterated
07/07/26
Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)
Morgan Stanley Analyst forecast on MX:CMPSN
Judah Frommer
Morgan Stanley
Morgan Stanley
$297.65
Buy
―
Reiterated
07/07/26
Compass new data validates COMP360 durability profile, says Morgan StanleyCompass new data validates COMP360 durability profile, says Morgan Stanley
Maxim Group Analyst forecast on MX:CMPSN
Michael Okunewitch
Maxim Group
Maxim Group
$350.18
Buy
―
Assigned
05/15/26
Compass Pathways price target raised to $20 from $12 at MaximCompass Pathways price target raised to $20 from $12 at Maxim
Jefferies Analyst forecast on MX:CMPSN
Andrew Tsai
Jefferies
Jefferies
$315.16
Buy
―
Reiterated
05/14/26
Jefferies Remains a Buy on COMPASS Pathways (CMPS)
B. Riley Securities Analyst forecast on MX:CMPSN
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$297.65
Buy
―
Initiated
04/24/26
Compass Pathways initiated with a Buy at B. RileyCompass Pathways initiated with a Buy at B. Riley
Cantor Fitzgerald Analyst forecast on MX:CMPSN
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$350.18
Buy
―
Reiterated
01/07/26
Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
ENOVEnovis
GKOSGlaukos
IFRXInflaRx
BKDBrookdale Senior Living
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

3 Months
Michael OkunewitchMaxim Group
Success Rate
8/11 ratings generated profit
73%
Average Return
+33.43%
Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +33.43% per trade.
1 Year
Michael OkunewitchMaxim Group
Success Rate
9/11 ratings generated profit
82%
Average Return
+99.50%
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +99.50% per trade.
2 Years
Michael OkunewitchMaxim Group
Success Rate
11/11 ratings generated profit
100%
Average Return
+128.87%
Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +128.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPSN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
29
28
30
18
22
Buy
1
1
2
3
5
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
30
32
21
27
In the current month, CMPSN has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CMPSN average Analyst price target in the past 3 months is 437.72.
Each month's total comprises the sum of three months' worth of ratings.

CMPSN Financial Forecast

CMPSN Earnings Forecast

Next quarter’s earnings estimate for CMPSN is -$6.76 with a range of -$12.26 to -$4.73. The previous quarter’s EPS was $12.43. CMPSN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year CMPSN has Performed in-line its overall industry.
Next quarter’s earnings estimate for CMPSN is -$6.76 with a range of -$12.26 to -$4.73. The previous quarter’s EPS was $12.43. CMPSN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year CMPSN has Performed in-line its overall industry.
No data currently available

CMPSN Sales Forecast

Next quarter’s sales forecast for CMPSN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPSN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year CMPSN has Performed in-line its overall industry.
Next quarter’s sales forecast for CMPSN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPSN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year CMPSN has Performed in-line its overall industry.

CMPSN Stock Forecast FAQ

What is MX:CMPSN’s average 12-month price target, according to analysts?
Based on analyst ratings, Compass Pathways Plc’s 12-month average price target is 437.72.
    What is MX:CMPSN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:CMPSN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Compass Pathways Plc a Buy, Sell or Hold?
        Compass Pathways Plc has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Compass Pathways Plc’s share price target?
          The average share price target for Compass Pathways Plc is 437.72. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $1,225.62 ,and the lowest forecast is $297.65. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Compass Pathways Plc?
            Compass Pathways Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of Compass Pathways Plc?
              To buy shares of MX:CMPSN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.